Legislation · Canada (Federal) · Federal
C-265 — An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)
Clarion tracks C-265 before Canada (Federal) — its status, sponsor, plain-language summary, and every stage it moves through, each cited to the official record.
- Status
- In committee — House of Commons
- Sponsor
- Marcus Powlowski
- Introduced
- 2026-03-11
- Session
- 45-1
Policy areas
See what's moving in Canadian policy — get The Dispatch, our free weekly read.
What it does
AI plain-language summary of the official text.
Bill C-265 is a Private Member's Bill introduced in the 45th Parliament that would amend the Food and Drugs Act to establish a list of therapeutic products pre-approved for special access. The bill passed second reading in the House of Commons in June 2026 and is currently under consideration by a House committee. The special access program generally allows patients to obtain drugs or medical devices not otherwise available in Canada, and this bill appears aimed at streamlining that process through pre-approved product listings.
Passage outlook
Contested because it's a private member's bill (which rarely passes), it's at committee.
Historically 0–5% of comparable federal bills became law (base rate 4%).
If this private member's bill would create new spending, it needs a Royal Recommendation (Cabinet only) — without one, passage is effectively nil.
A private member's bill's fate hinges on its position in the Order of Precedence (a random draw) — bills low on the list often run out of calendar time.
A transparent, rule-based outlook from bill type, stage, and verified government standing — not a guaranteed prediction.
Track C-265 — and everything like it
Set a topic, and Clarion grades the bills, debates, and lobbying filings it ingests to your files — with a calibrated passage forecast and an AI clerk that answers from the record and cites it.